Carlos Trescolí

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD

Andrew S. Allegretti, Wenbin Zhang, Wenjiong Zhou et al. · American Journal of Kidney Diseases · 2019 · 87 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial

Julio Rosenstock, Rıfat Emral, Leobardo Sauque‐Reyna et al. · Diabetes Care · 2021 · 58 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial

Graydon S. Meneilly, Christine Roy-Duval, Hasan Alawi et al. · Diabetes Care · 2017 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +17